SCIE

HoneyNaps Receives U.S. FDA Approval for Groundbreaking AI Sleep Disorder Diagnosis Software

Retrieved on: 
Monday, September 25, 2023
Posture, Polysomnography, Sleep, AlphaGo, WSS, Research, Snoring, XAI, Facial muscles, Sleep disorder, SCIE, Reading, Diagnosis, AI, Chin, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical device, Pharmaceutical industry

SEOUL, South Korea, Sept. 25, 2023 /PRNewswire/ -- HoneyNaps, the leading-edge AI-based sleep disorder diagnosis software company, has announced that its SOMNUM AI sleep disease analysis algorithm has been approved by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • SEOUL, South Korea, Sept. 25, 2023 /PRNewswire/ -- HoneyNaps, the leading-edge AI-based sleep disorder diagnosis software company, has announced that its SOMNUM AI sleep disease analysis algorithm has been approved by the U.S. Food and Drug Administration (FDA).
  • AI and medical devices are a sought-after combination, but the FDA has granted only two approvals for sleep disease diagnosis solutions by U.S. companies.
  • HoneyNaps is the first Korean company and identify their FDA approval as a demonstration of their technology's capabilities.
  • Sleep biosignals tend to include electroencephalograms, electrooculograms, chin and leg electromyograms, electrocardiograms, respiratory airflow and effort, oxygen saturation, posture, and snoring, and these are monitored continuously during sleep for assessing sleep status and sleep disorder diagnosis via polysomnography.

Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Retrieved on: 
Wednesday, September 13, 2023
Biotechnology, Pharmaceutical, Health, Lymphoma, IRC, Independent Review Committee, Journal, Progression-free survival, Hematology, DOR, Non-Hodgkin lymphoma, NHL, Neoplasm, American Journal of Hematology, BTK, PFS, Incidence, American Journal, Spleen, Patient, Lymph, Mantle cell lymphoma, SCIE, MCL, SCI, Marginal zone B-cell lymphoma, ORR, Safety, Pharmaceutical industry, Medical device

American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL), which investigated the efficacy and safety of orelabrutinib in r/r MZL.

Key Points: 
  • American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL), which investigated the efficacy and safety of orelabrutinib in r/r MZL.
  • The journal concluded that orelabrutinib demonstrated high response rates with durable disease remission and was well tolerated in patients with relapsed or refractory MZL.
  • The journal concluded that orelabrutinib produced a robust response and was well tolerated in r/r MZL patients.
  • The American Journal of Hematology is an academic journal focusing on hematology, which was founded in 1976 and published monthly by WILEY publisher.

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Retrieved on: 
Thursday, May 25, 2023
Medical school, PRS, Korea University, Enzyme, Homeostasis, Molecular medicine, Yonsei University, EMBO, Science Citation Index Expanded, KDDF, Patient, EMBO Molecular Medicine, SCIE, School, Medicine, Pharmacy school, Drug discovery, IPF, Idiopathic pulmonary fibrosis, Safety, Pharmaceutical industry, Pharmacy, Fibrosis, Daewoong Pharmaceutical

SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.

Key Points: 
  • SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.
  • EMBO Molecular Medicine is a SCIE (Science Citation Index Expanded) journal.
  • EMBO is a world-renowned journal with an impact factor 14.005, has a ranking of top 5%.
  • Therefore, Bersiporocin can bring antifibrotic effect through reduced enzymatic activity while still maintaining its critical function in homeostasis.

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Retrieved on: 
Thursday, May 25, 2023
Medical school, PRS, Korea University, Enzyme, Homeostasis, Molecular medicine, Yonsei University, EMBO, Science Citation Index Expanded, KDDF, Patient, EMBO Molecular Medicine, SCIE, School, Medicine, Pharmacy school, Drug discovery, IPF, Idiopathic pulmonary fibrosis, Safety, Pharmaceutical industry, Pharmacy, Fibrosis, Daewoong Pharmaceutical

SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.

Key Points: 
  • SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.
  • EMBO Molecular Medicine is a SCIE (Science Citation Index Expanded) journal.
  • EMBO is a world-renowned journal with an impact factor 14.005, has a ranking of top 5%.
  • Therefore, Bersiporocin can bring antifibrotic effect through reduced enzymatic activity while still maintaining its critical function in homeostasis.

Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology

Retrieved on: 
Tuesday, February 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, American Journal of Hematology, CR, Journal, CLL, OS, TP53, Nanjing Medical University, Aes, Patient, IGHV, SCI, SCIE, The First Affiliated Hospital of Wenzhou Medical University, American Journal, First Affiliated Hospital of Xinjiang Medical University, Malignancy, Lymphocytosis, ORR, Progression-free survival, SLL, Chronic lymphocytic leukemia, Observation, BTK, PFS, Leukemia, Death, Pharmaceutical industry, Relapse, Hematology

American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.

Key Points: 
  • American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.
  • The journal concluded that monotherapy of orelabrutinib demonstrated compelling efficacy and a well-tolerated safety profile, with a significant number of patients achieving CR in R/R CLL/SLL.
  • The American Journal of Hematology is an academic journal focusing on hematology, which was founded in 1976 and published monthly by WILEY publisher.
  • Note: In addition to background information, the content of this press release is derived from this published article.

WAYCEN, the first medical AI company to win 4 CES 2023 innovation awards "Proved K-Medtech"

Retrieved on: 
Thursday, January 5, 2023
Lung cancer, AME Publishing Company, Electronics, Research, Record, Artificial intelligence, CES, Smartphone, Odyssey Software (Mobile Device Management), Respiratory system, Deep learning, Digital, Metastasis, SCIE, Endo, Exhibition, Cough, CTA, Severance Hospital, AI, Software, Consumer Technology Association, Gangneung Asan Hospital, EBUS, Lymph, National Association Medical Staff Services, Engineering, Human, Endoscopy, Diagnosis, Medical device, Medical imaging, Industrial design

Company specialized in AI Medtech, WAYCEN, won CES innovation awards for two years in a row

Key Points: 
  • Company specialized in AI Medtech, WAYCEN, won CES innovation awards for two years in a row
    WAYCEN swept CES 2023 innovation awards with medical AI products, collaborated with the medical staff
    SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- The company specialized in AI Medtech, WAYCEN (CEO Kyungnam Kim) made splendid achievements of winning four CES innovation awards for the first time among medical AI companies ahead of 'CES 2023', the world's largest electronics exhibition, which will be held in Las Vegas, United States, in next January.
  • Winning two awards solely for the products utilizing the real-time image analysis technology is to highlight innovations in WAYCEN's medical AI solution lineup.
  • It speaks volumes within the medical industry that medical professionals and AI-specialized company jointly developed clinically useful products through technical verifications and accomplished such great performance.
  • Also, it is the AI medtech-specialized company that was selected as the "Country Representative Innovation Company 1000'" and "MEDTECH INNOVATOR APAC TOP 4".

LifeOmic and Indiana University School of Medicine Collaborate on the Largest Real-World Intermittent Fasting Study

Retrieved on: 
Tuesday, October 4, 2022
People, Cloud, University School, YouTube, Fasting, Journal, Obesity, U.S. News & World Report, MHealth, Ageing, Communication, LIFE, IF, Research, Population, Weight loss, MEDLINE, Clarivate, Journal of Medical Internet Research, Health, PubMed Central, DOAJ, JMIR, Indiana University School of Medicine, Machine learning, Diagnosis, Impact factor, Adult, Time, Learning, Reproduction, Lists of diseases, Prevalence, Twitter, PsycINFO, JCR, Publication, Weight, Creative Commons license, Maintenance, Solution, Indiana University, Overweight, Ownership, Technology, LinkedIn, EBSCO, Outline of health sciences, Instagram, Safety, Observational study, Eating, SCIE, Reinier Nooms, Intermittency, News, Medical device, Mobile phone, Tourism, Medicine, Facebook, PubMed

INDIANAPOLIS, Oct. 4, 2022 /PRNewswire/ -- LifeOmic, a software company leveraging the cloud, machine learning, and mobile devices to power precision health and wellness solutions, today unveiled findings from a landmark intermittent fasting (IF) study conducted with scientists from Indiana University School of Medicine. The study, published in JMIR mHealth and uHealth, quantifies user retention, fasting patterns, and weight loss in users of LifeOmic's LIFE Apps suite of mobile apps: LIFE Fasting Tracker (LifeOmic's fasting app) and LIFE Extend (LifeOmic's Precision Wellness app). It is the largest research study of its kind to date, following nearly 800,000 users and tracking 26 million fasts over 2 years.

Key Points: 
  • It is the largest research study of its kind to date, following nearly 800,000 users and tracking 26 million fasts over 2 years.
  • We're proud of our research with renowned scientists at Indiana University School of Medicine, which looks at intermittent fasting behavior in the real world.
  • Retention, Fasting Patterns, and Weight Loss With an Intermittent Fasting App: Large-Scale, 52-Week Observational Study.
  • To learn more about LifeOmic visit lifeomic.com
    Indiana University School of Medicine:
    IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report.

Clarivate announces changes to the 2023 Journal Citation Reports All Web of Science Core Collection journals, including arts and humanities will have Journal Impact Factors

Retrieved on: 
Tuesday, July 26, 2022
Social Sciences Citation Index, Western literature, Improper integral, Editorial, AHCI, Professional services, Global South, Gold, Technology, Policy, Review, Ecosystem, Librarian, Journal Citation Reports, Institute for Scientific Information, Science Citation Index, CVS, Impact factor, Research, Solution, Clarivate, Arts and Humanities Citation Index, JCR, JIF, Metric, Emerging Sources Citation Index, Web of Science, List of life sciences, Health care, ISI, Twitter, Final good, Institute, Academy, Publication, The arts, Humanities, ESCI, EU, SSCI, Center, Factor X, International Society for Scientometrics and Informetrics, NYSE, CWTS, Behavior, SCIE, Leiden University, Invention, Science and Technology Select Committee, Pharmaceutical industry, Periodical literature, Publishing, Book, Medical device, Management, Science

This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citation Index (AHCI)and the multidisciplinary Emerging Sources Citation Index (ESCI).

Key Points: 
  • This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citation Index (AHCI)and the multidisciplinary Emerging Sources Citation Index (ESCI).
  • I welcome the expansion of the JIF to all journals in Web of Science Core Collection.
  • These include:
    The Journal Citation Indicator, which represents the average category-normalized citation impact for papers published in the prior three-year period.
  • You can find more information including our suppression policy in the Journal Citation Reports Reference Guide .

Clarivate announces changes to the 2023 Journal Citation Reports All Web of Science Core Collection journals, including arts and humanities will have Journal Impact Factors

Retrieved on: 
Tuesday, July 26, 2022
Social Sciences Citation Index, Western literature, Improper integral, Editorial, AHCI, Professional services, Global South, Gold, Technology, Policy, Review, Ecosystem, Librarian, Journal Citation Reports, Institute for Scientific Information, Science Citation Index, CVS, Impact factor, Research, Solution, Clarivate, Arts and Humanities Citation Index, JCR, JIF, Metric, Emerging Sources Citation Index, Web of Science, List of life sciences, Health care, ISI, Twitter, Final good, Institute, Academy, Publication, The arts, Humanities, ESCI, EU, SSCI, Center, Factor X, International Society for Scientometrics and Informetrics, NYSE, CWTS, Behavior, SCIE, Leiden University, Invention, Science and Technology Select Committee, Pharmaceutical industry, Periodical literature, Publishing, Book, Medical device, Management, Science

This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citation Index (AHCI)and the multidisciplinary Emerging Sources Citation Index (ESCI).

Key Points: 
  • This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citation Index (AHCI)and the multidisciplinary Emerging Sources Citation Index (ESCI).
  • I welcome the expansion of the JIF to all journals in Web of Science Core Collection.
  • These include:
    The Journal Citation Indicator, which represents the average category-normalized citation impact for papers published in the prior three-year period.
  • You can find more information including our suppression policy in the Journal Citation Reports Reference Guide .

Clarivate Names World's Leading Journals with the 2022 Journal Citation Reports

Retrieved on: 
Tuesday, June 28, 2022
Factor X, Academy, The New England Journal of Medicine, Critical care, Nature Reviews Molecular Cell Biology, SSCI, Publication, Journal, Invention, Research, JCR, Technology, Clarivate, SCIE, Bya, Health and wellbeing board, Book, COVID-19, Internal medicine, Blog, Drug discovery, Sustainable development, Journal Citation Reports, Health care, Final good, Public health, UN, Policy, Infection, Literature, JIF, Journal of General Internal Medicine, List of life sciences, NYSE, Librarian, Editorial, JAMA, The Lancet, Nature Reviews Drug Discovery, Solution, Jif, Vaccine, Professional services, Impact factor, Twitter, American Medical Association, Collection, Pharmaceutical industry, Medical device, Periodical literature, Health, Lancet

LONDON, June 28, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released the 2022 update to its annual Journal Citation Reports (JCR)™. The annual JCR release enables the research community to evaluate the world's high-quality academic journals using a range of indicators, descriptive data and visualizations. The reports are used extensively by academic publishers across the globe to understand the scholarly impact of their journals relative to their field and promote them to the research community. 

Key Points: 
  • LONDON, June 28, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released the 2022 update to its annual Journal Citation Reports (JCR) .
  • Clarivate monitors and excludes journals that demonstrate anomalous citation behavior including where there is evidence of excessive journal self-citation and/or citation stacking.
  • Key facts from the 2021 data:
    The Journal Citation Reports contains more than 21,000 journals, from 254 research categories and 114 countries.
  • These include:
    The Journal Citation Indicator, which represents the average category-normalized citation impact for papers published in the prior three-year period.